Accessibility Statement Skip Navigation
  • Resources
  • Investor Relations
  • Journalists
  • Agencies
  • Client Login
  • Send a Release
Return to PR Newswire homepage
  • News
  • Products
  • Contact
Search
When typing in this field, a list of search results will appear and be automatically updated as you type.

Searching for your content...

No results found. Please change your search terms and try again.
  • News Releases view all

    • News in Focus
        • Browse News Releases

        • All News Releases
        • All Public Company
        • English-only
        • News Releases Overview

        • Multimedia Gallery

        • All Multimedia
        • All Photos
        • All Videos
        • Multimedia Gallery Overview

        • Trending Topics

        • All Trending Topics
    • Business & Money
        • Auto & Transportation

        • Aerospace, Defense
        • Air Freight
        • Airlines & Aviation
        • Automotive
        • Maritime & Shipbuilding
        • Railroads and Intermodal Transportation
        • Supply Chain/Logistics
        • Transportation, Trucking & Railroad
        • Travel
        • Trucking and Road Transportation
        • Auto & Transportation Overview

        • View All Auto & Transportation

        • Business Technology

        • Blockchain
        • Broadcast Tech
        • Computer & Electronics
        • Computer Hardware
        • Computer Software
        • Data Analytics
        • Electronic Commerce
        • Electronic Components
        • Electronic Design Automation
        • Financial Technology
        • High Tech Security
        • Internet Technology
        • Nanotechnology
        • Networks
        • Peripherals
        • Semiconductors
        • Business Technology Overview

        • View All Business Technology

        • Entertain­ment & Media

        • Advertising
        • Art
        • Books
        • Entertainment
        • Film and Motion Picture
        • Magazines
        • Music
        • Publishing & Information Services
        • Radio & Podcast
        • Television
        • Entertainment & Media Overview

        • View All Entertain­ment & Media

        • Financial Services & Investing

        • Accounting News & Issues
        • Acquisitions, Mergers and Takeovers
        • Banking & Financial Services
        • Bankruptcy
        • Bond & Stock Ratings
        • Conference Call Announcements
        • Contracts
        • Cryptocurrency
        • Dividends
        • Earnings
        • Earnings Forecasts & Projections
        • Financing Agreements
        • Insurance
        • Investments Opinions
        • Joint Ventures
        • Mutual Funds
        • Private Placement
        • Real Estate
        • Restructuring & Recapitalization
        • Sales Reports
        • Shareholder Activism
        • Shareholder Meetings
        • Stock Offering
        • Stock Split
        • Venture Capital
        • Financial Services & Investing Overview

        • View All Financial Services & Investing

        • General Business

        • Awards
        • Commercial Real Estate
        • Corporate Expansion
        • Earnings
        • Environmental, Social and Governance (ESG)
        • Human Resource & Workforce Management
        • Licensing
        • New Products & Services
        • Obituaries
        • Outsourcing Businesses
        • Overseas Real Estate (non-US)
        • Personnel Announcements
        • Real Estate Transactions
        • Residential Real Estate
        • Small Business Services
        • Socially Responsible Investing
        • Surveys, Polls and Research
        • Trade Show News
        • General Business Overview

        • View All General Business

    • Science & Tech
        • Consumer Technology

        • Artificial Intelligence
        • Blockchain
        • Cloud Computing/Internet of Things
        • Computer Electronics
        • Computer Hardware
        • Computer Software
        • Consumer Electronics
        • Cryptocurrency
        • Data Analytics
        • Electronic Commerce
        • Electronic Gaming
        • Financial Technology
        • Mobile Entertainment
        • Multimedia & Internet
        • Peripherals
        • Social Media
        • STEM (Science, Tech, Engineering, Math)
        • Supply Chain/Logistics
        • Wireless Communications
        • Consumer Technology Overview

        • View All Consumer Technology

        • Energy & Natural Resources

        • Alternative Energies
        • Chemical
        • Electrical Utilities
        • Gas
        • General Manufacturing
        • Mining
        • Mining & Metals
        • Oil & Energy
        • Oil and Gas Discoveries
        • Utilities
        • Water Utilities
        • Energy & Natural Resources Overview

        • View All Energy & Natural Resources

        • Environ­ment

        • Conservation & Recycling
        • Environmental Issues
        • Environmental Policy
        • Environmental Products & Services
        • Green Technology
        • Natural Disasters
        • Environment Overview

        • View All Environ­ment

        • Heavy Industry & Manufacturing

        • Aerospace & Defense
        • Agriculture
        • Chemical
        • Construction & Building
        • General Manufacturing
        • HVAC (Heating, Ventilation and Air-Conditioning)
        • Machinery
        • Machine Tools, Metalworking and Metallurgy
        • Mining
        • Mining & Metals
        • Paper, Forest Products & Containers
        • Precious Metals
        • Textiles
        • Tobacco
        • Heavy Industry & Manufacturing Overview

        • View All Heavy Industry & Manufacturing

        • Telecomm­unications

        • Carriers and Services
        • Mobile Entertainment
        • Networks
        • Peripherals
        • Telecommunications Equipment
        • Telecommunications Industry
        • VoIP (Voice over Internet Protocol)
        • Wireless Communications
        • Telecommunications Overview

        • View All Telecomm­unications

    • Lifestyle & Health
        • Consumer Products & Retail

        • Animals & Pets
        • Beers, Wines and Spirits
        • Beverages
        • Bridal Services
        • Cannabis
        • Cosmetics and Personal Care
        • Fashion
        • Food & Beverages
        • Furniture and Furnishings
        • Home Improvement
        • Household, Consumer & Cosmetics
        • Household Products
        • Jewelry
        • Non-Alcoholic Beverages
        • Office Products
        • Organic Food
        • Product Recalls
        • Restaurants
        • Retail
        • Supermarkets
        • Toys
        • Consumer Products & Retail Overview

        • View All Consumer Products & Retail

        • Entertain­ment & Media

        • Advertising
        • Art
        • Books
        • Entertainment
        • Film and Motion Picture
        • Magazines
        • Music
        • Publishing & Information Services
        • Radio & Podcast
        • Television
        • Entertainment & Media Overview

        • View All Entertain­ment & Media

        • Health

        • Biometrics
        • Biotechnology
        • Clinical Trials & Medical Discoveries
        • Dentistry
        • FDA Approval
        • Fitness/Wellness
        • Health Care & Hospitals
        • Health Insurance
        • Infection Control
        • International Medical Approval
        • Medical Equipment
        • Medical Pharmaceuticals
        • Mental Health
        • Pharmaceuticals
        • Supplementary Medicine
        • Health Overview

        • View All Health

        • Sports

        • General Sports
        • Outdoors, Camping & Hiking
        • Sporting Events
        • Sports Equipment & Accessories
        • Sports Overview

        • View All Sports

        • Travel

        • Amusement Parks and Tourist Attractions
        • Gambling & Casinos
        • Hotels and Resorts
        • Leisure & Tourism
        • Outdoors, Camping & Hiking
        • Passenger Aviation
        • Travel Industry
        • Travel Overview

        • View All Travel

    • Policy & Public Interest
        • Policy & Public Interest

        • Advocacy Group Opinion
        • Animal Welfare
        • Congressional & Presidential Campaigns
        • Corporate Social Responsibility
        • Domestic Policy
        • Economic News, Trends, Analysis
        • Education
        • Environmental
        • European Government
        • FDA Approval
        • Federal and State Legislation
        • Federal Executive Branch & Agency
        • Foreign Policy & International Affairs
        • Homeland Security
        • Labor & Union
        • Legal Issues
        • Natural Disasters
        • Not For Profit
        • Patent Law
        • Public Safety
        • Trade Policy
        • U.S. State Policy
        • Policy & Public Interest Overview

        • View All Policy & Public Interest

    • People & Culture
        • People & Culture

        • Aboriginal, First Nations & Native American
        • African American
        • Asian American
        • Children
        • Diversity, Equity & Inclusion
        • Hispanic
        • Lesbian, Gay & Bisexual
        • Men's Interest
        • People with Disabilities
        • Religion
        • Senior Citizens
        • Veterans
        • Women
        • People & Culture Overview

        • View All People & Culture

    • Explore Our Platform
    • Plan Campaigns
    • Create with AI
    • Distribute Press Releases
    • Report Results
    • Amplify Content
    • All Products
    • General Inquiries
    • Editorial Bureaus
    • Partnerships
    • Media Inquiries
    • Worldwide Offices
    • Hamburger menu
    • PR Newswire: news distribution, targeting and monitoring
    • Send a Release
      • ALL CONTACT INFO
      • Contact Us

        888-776-0942
        from 8 AM - 10 PM ET

    • Searching for your content...

      No results found. Please change your search terms and try again.

      News Releases

      view all
      Close menu
    • News
    • Products
    • Contact
      • Send a Release
      • Client Login
      • Resources
      • Blog
      • Journalists
      • RSS
      • 3 News in Focus
      • 5 Business & Money
      • 5 Science & Tech
      • 5 Lifestyle & Health
      • 1 Policy & Public Interest
      • 1 People & Culture
      • Send a Release
      • Client Login
      • Resources
      • Blog
      • Journalists
      • RSS
      • Explore Our Platform
      • Plan Campaigns
      • Create with AI
      • Distribute Press Releases
      • Report Results
      • Amplify Content
      • All Products
      • Send a Release
      • Client Login
      • Resources
      • Blog
      • Journalists
      • RSS
      • General Inquiries
      • Editorial Bureaus
      • Partnerships
      • Media Inquiries
      • Worldwide Offices
      • Send a Release
      • Client Login
      • Resources
      • Blog
      • Journalists
      • RSS
      Close submenu (News in Focus) News in Focus
      • Browse News Releases
      • Multimedia Gallery
      • Trending Topics
      Close submenu (Business & Money) Business & Money
      • Auto & Transportation
      • Business Technology
      • Entertain­ment & Media
      • Financial Services & Investing
      • General Business
      Close submenu (Science & Tech) Science & Tech
      • Consumer Technology
      • Energy & Natural Resources
      • Environ­ment
      • Heavy Industry & Manufacturing
      • Telecomm­unications
      Close submenu (Lifestyle & Health) Lifestyle & Health
      • Consumer Products & Retail
      • Entertain­ment & Media
      • Health
      • Sports
      • Travel
      Close submenu (Policy & Public Interest) Policy & Public Interest
      • Policy & Public Interest
      Close submenu (People & Culture) People & Culture
      • People & Culture

      Protego Presents New Data at ISA 2026 that Advances Evidence for Light-Chain Stabilization with PROT-001 in AL Amyloidosis

      Protego Biopharma logo

      News provided by

      Protego Biopharma

      Nov 16, 2026, 07:01 ET

      Share this article

      Share this article



      - PROT-001, the company's investigational oral small molecule drug for AL amyloidosis, demonstrated an acceptable safety and tolerability profile in a healthy volunteer Phase 1 study

      - In human cardiomyocyte and plasma cell studies, PROT-001 reduced markers of stress and toxicity, and demonstrated compatibility with standard-of-care bortezomib

      - Additional presentations highlight advanced detection of amyloidogenic light chains with Protego's AmyLiteDxTM assay, and use of NT-proBNP as an early clinical biomarker of cardiac response

      - Results support evaluating PROT-001 in planned Phase 2/3 SHIELD-AL study in AL amyloidosis patients

      SAN DIEGO, Nov. 16, 2026 /PRNewswire/ -- Protego Biopharma, Inc., a clinical-stage biotechnology company developing small-molecule therapies for protein misfolding diseases, today announced results from five presentations that highlight the Phase I clinical and preclinical profile of PROT-001, the company's potential first-in-class, investigational lambda light chain kinetic stabilizer to treat light chain (AL) amyloidosis. The presentations at the XX International Symposium on Amyloidosis (ISA 2026), taking place November 15-18, 2026, come on the heels of Protego receiving clearance from the United States Food and Drug Administration (FDA) to proceed with SHIELD-AL, its Phase 2/3 trial of PROT-001 in AL amyloidosis patients.

      PROT-001 is designed as a kinetic stabilizer of amyloidogenic light chains (LCs) and to neutralize their toxicity. Across the five ISA 2026 presentations, Protego presented data that, collectively, support the advancement of PROT-001 into pivotal studies.

      "Cardiac involvement is a major driver of morbidity and mortality in AL amyloidosis. Plasma cell-directed therapies reduce the production of light chains, but circulating amyloidogenic light chains can continue to damage the heart," said Brent J. Warner, MBA, Chief Executive Officer of Protego. "PROT-001 is designed to complement these treatments by stabilizing amyloidogenic light chains and reducing their toxicity. The data presented at ISA 2026 strengthen the rationale for SHIELD-AL, where we will evaluate whether this approach can deliver earlier and deeper cardiac responses."

      Detailed results from Protego's five poster presentations are as follows:

      PROT-001, a first-in-class lambda light chain kinetic stabilizer for AL amyloidosis: Results from the Phase I PRO-1A-101 Study (Abstract 32458)
      PRO-1A-101 evaluated the safety, tolerability, pharmacokinetics (PK), and pharmacodynamics (PD) of PROT-001 in 102 healthy volunteers, in four study parts: a randomized, placebo-controlled single ascending dose (SAD), a multiple ascending dose (MAD) study, an open-label food effect (FE) study, and an open-label drug-drug interaction (DDI) study.

      In the study, twice-daily oral dosing of PROT-001 was generally safe and well-tolerated and achieved plasma levels associated with sustained ex vivo stabilization of amyloidogenic lambda light chains, supporting the proposed mechanism of action and further development of PROT-001 in patients with AL amyloidosis. The PK and PD results supported further development of orally administered PROT-001 dosed 300-600 mg twice a day.

      PROT-001 Suppresses Amyloidogenic Light Chain Induced BNP Signaling and Cardiotoxicity in Human Cardiomyocytes (Abstract 32266)
      PROT-001 helped protect human heart cells from the harmful effects of amyloid-forming light chains, reducing markers of stress and damage in cell-based studies. The results demonstrate the potential of PROT-001 as a disease-modifying therapy that may provide an organ-protective benefit.

      Amyloidogenic LCs reduced cardiomyocyte viability by >50%, while non-amyloidogenic LCs did not affect viability. PROT-001 restored viability in a dose-dependent manner and selectively suppressed expression of BNP and troponin, which are markers of cardiac stress and cardiotoxicity, respectively.

      PROT-001 Demonstrates Compatibility with Bortezomib-Based Regimens While Preserving Plasma Cell Cytotoxicity (Abstract Number 32147)
      Data demonstrate that PROT-001 did not reduce the plasma cell-killing activity of bortezomib, a component of standard-of-care treatment regimens, or worsen its toxic effects on human heart cells. These findings support further evaluation of PROT-001 if used with bortezomib-based regimens.

      AmyLiteDx™: A Mass Spectrometry-Based Platform for Sensitive and In-Depth Analysis of Amyloidogenic Immunoglobulin Light Chains in AL Amyloidosis (Abstract 32645)
      Current immunoassay-based methods measure circulating LC concentration but do not directly assess LC instability. Protego's AmyLiteDx assay is a next-generation, mass spectrometry-based platform that enables deeper characterization and monitoring of unstable, toxic LCs alongside conventional biomarkers.

      Retrospective Study Evaluating Cardiac Biomarkers in Patients with AL Cardiac Amyloidosis (Abstract 32646)
      This retrospective study evaluated NT-proBNP, a biomarker of cardiac stress and toxicity, in newly diagnosed Mayo stage II-IIIb AL amyloidosis patients receiving standard-of-care therapy. The study data showed that NT-proBNP reduction in six-month cardiac organ responders was most apparent within the first 28 days, and that early cardiac response was associated with improved overall survival over the long term. These findings support investigational therapeutic approaches that can more rapidly and potently address amyloidogenic light-chain toxicity to improve rates of early cardiac organ response.

      About Protego Biopharma 
      Protego Biopharma is a clinical-stage biotechnology company developing first-in-class small molecule therapies for AL amyloidosis and other protein misfolding diseases. Protego aims to translate advances in protein stabilization into medicines that address the misfolding and toxicity responsible for progressive organ damage. Its therapies are designed to intervene in this disease process, with the goal of preserving organ function and improving patients' lives. For more information, visit www.protegobio.com. 

      About PROT-001
      PROT-001 is Protego Biopharma's lead investigational small molecule pharmacological chaperone, being developed for the treatment of immunoglobulin light chain (AL) amyloidosis. PROT-001 is designed to stabilize amyloidogenic lambda light chain proteins and prevent misfolding and the formation of proteotoxic species. The goal of this therapy is to limit the toxic effects that contribute to organ injury, including direct damage to cardiomyocytes in AL patients. PROT-001 represents a complementary approach to plasma cell-directed therapies, which reduce light chain production. By targeting the amyloidogenic light chain protein before it can adopt a pathogenic conformation, PROT-001 has the potential to complement existing treatments and address an additional mechanism of disease. 

      About PRO-1A-101
      PRO-1A-101 (NCT06981299) was a first-in-human, four-part Phase 1 study that evaluated the safety, tolerability, pharmacokinetics (PK), pharmacodynamics (PD), food effect (FE) and drug-drug interaction (DDI) potential of PROT-001 in healthy adult participants. Part 1 randomized participants to receive single ascending doses (SAD) of up to 1350 mg of PROT-001 or placebo; Part 2 randomized participants to receive multiple ascending doses (MAD) of up to 600 mg twice daily of PROT-001 or placebo for 14 days. Part 3 consisted of a non-randomized FE study in participants receiving one dose of PROT-001 after fasting and one dose immediately after consuming meal. Part 4 was a non-randomized, open-label study that evaluated the potential DDIs of PROT-001 on the PK of a two-cocktail probe containing digoxin and rosuvastatin.

      About AL amyloidosis 
      Immunoglobulin light chain (AL) amyloidosis is a rare, life-threatening disease affecting over 5,100 newly diagnosed patients annually and 28,000 US adults in which abnormal plasma cells produce light chain proteins that can misfold and aggregate. The direct toxicity of disease-related light chains and their accumulation as amyloid deposits in tissues both result in injury to organs, including the heart and kidneys. Cardiac injury is particularly serious, as toxic light chains can directly impair cardiomyocyte function, while amyloid deposits disrupt the structure and function of the heart. Current treatments focus on reducing light chain production with plasma cell-directed therapies and managing organ complications, leaving patients with a substantial need for complementary approaches that directly address light chain toxicity and improve organ outcomes. 

      SOURCE Protego Biopharma

      Modal title

      Also from this source

      Protego to Highlight PROT-001's Potential to Target Light Chain Toxicity in AL Amyloidosis at ISA 2026

      Protego to Highlight PROT-001's Potential to Target Light Chain Toxicity in AL Amyloidosis at ISA 2026

      Protego Biopharma, Inc., a clinical-stage biotechnology company developing small-molecule therapies for protein misfolding diseases, today announced...

      Protego Announces FDA IND Clearance for Phase 2/3 Study of PROT-001 in AL Amyloidosis

      Protego Announces FDA IND Clearance for Phase 2/3 Study of PROT-001 in AL Amyloidosis

      Protego Biopharma, Inc., a clinical-stage biotechnology company developing small molecule therapies for protein misfolding diseases, today announced...

      More Releases From This Source

      Explore

      Medical Pharmaceuticals

      Medical Pharmaceuticals

      Health Care & Hospitals

      Health Care & Hospitals

      Pharmaceuticals

      Pharmaceuticals

      Biotechnology

      Biotechnology

      News Releases in Similar Topics

      Contact PR Newswire

      • Call PR Newswire at 888-776-0942
        from 8 AM - 9 PM ET
      • Chat with an Expert
      • General Inquiries
      • Editorial Bureaus
      • Partnerships
      • Media Inquiries
      • Worldwide Offices

      Products

      • Explore Our Platform
      • Plan Campaigns
      • Create with AI
      • Distribute Press Releases
      • Report Results
      • Amplify Content

      About

      • About PR Newswire
      • About Cision
      • Careers
      • Accessibility Statement
      • APAC
      • APAC - Simplified Chinese
      • APAC - Traditional Chinese
      • Brazil
      • Canada
      • Czech
      • Denmark
      • Finland
      • France
      • Germany
      • India
      • Indonesia
      • Israel
      • Italy
      • Japan
      • Korea
      • Mexico
      • Middle East
      • Middle East - Arabic
      • Netherlands
      • Norway
      • Poland
      • Portugal
      • Russia
      • Slovakia
      • Spain
      • Sweden
      • United Kingdom
      • Vietnam

      My Services

      • All New Releases
      • Platform Login
      • Data Privacy

      Do not sell or share my personal information:

      • Submit via [email protected] 
      • Call Privacy toll-free: 877-297-8921

      Contact PR Newswire

      Products

      About

      My Services
      • All News Releases
      • Platform Login
      • ProfNet
      Call PR Newswire at
      888-776-0942
      • Terms of Use
      • Privacy Policy
      • Information Security Policy
      • Site Map
      • RSS
      • Cookies
      Copyright © 2026 Cision US Inc.